Wegovy (semaglutide) is approved by the U.S. Food and Drug Administration (FDA) for weight loss and weight management in ...

THURSDAY, June 5, 2025 (HealthDay News) — More American teenagers now use the weight-loss drug Wegovy, as doctors and ...

Sara Moniuszko is a health and lifestyle reporter at CBSNews.com. Previously, she wrote for USA Today, where she was selected to help launch the newspaper's wellness vertical. She now covers ...

A new study has found that people taking Eli Lilly's obesity drug Zepbound lost almost 50% more weight than those using Novo Nordisk's Wegovy. The study, published in the New England Journal of ...

A trial was conducted comparing weight loss medications Zepbound and Wegovy. Results from the trial found that participants who took Zepbound lost more weight than those who took Wegovy.

Wegovy-maker Novo Nordisk has pushed out CEO Lars Fruergaard Jorgensen over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market. Novo Nordisk ...

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50 percent more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.

The weight loss drug Zepbound (tirzepatide) led to 50 percent more weight loss in a 72-week trial than Wegovy (semaglutide). Participants taking Zepbound lost 50 pounds (lb) on average ...

Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds over 72 weeks, while those who took semaglutide, or Wegovy, lost about 33 pounds (15 ...

Share on Pinterest A Wegovy weight loss pill from Novo Nordisk is forthcoming, providing an alternative to injectable GLP-1 drugs. Mads Claus Rasmussen/Ritzau Scanpix/AFP via Getty Images Federal ...

Patients on GLP-1 agonists Wegovy and Ozempic reported flu-like symptoms, fatigue, abdominal cramps and vomiting, thought to be related to liver injury. The most severe cases were rushed to ...